题目信息
Symptoms of Parkinson's Disease, such as tremors, are thought to be caused by low dopamine levels in the brain. Current treatments of Parkinson's disease are primarily reactionary, aiming to replenish dopamine levels after dopamine-producing neurons in the brain have died. Without a more detailed understanding of the behavior of dopamine-producing neurons, it has been impossible to develop treatments that would prevent the destruction of these neurons in Parkinson's patients.
Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alpha-synuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.
With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell. Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.
While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients. Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson's patients, but other causes may exist. Most scientists involved with Parkinson's research do agree, however, that such promising early results provide a basis for further testing.
Recent research provides insight into the inner workings of dopamine-producing neurons, and may lead to a new drug treatment that would proactively protect the neurons from decay. By examining the alpha-synuclein protein in yeast cells, scientists have determined that toxic levels of the protein have a detrimental effect on protein transfer within the cell. More specifically, high levels of alpha-synuclein disrupt the flow of proteins from the endoplasmic reticulum, the site of protein production in the cell, to the Golgi apparatus, the component of the cell that modifies and sorts the proteins before sending them to their final destinations within the cell. When the smooth transfer of proteins from the endoplasmic reticulum to the Golgi apparatus is interrupted, the cell dies.
With this in mind, researchers conducted a genetic screen in yeast cells in order to identify any gene that works to reverse the toxic levels of alpha-synuclein in the cell. Researchers discovered that such a gene does in fact exist, and have located the genetic counterpart in mammalian nerve cells, or neurons. This discovery has led to new hopes that drug therapy could potentially activate this gene, thereby suppressing the toxicity of alpha-synuclein in dopamine-producing neurons.
While drug therapy to suppress alpha-synuclein has been examined in yeast, fruitflies, roundworms, and cultures of rat neurons, researchers are hesitant to conclude that such therapies will prove successful on human patients. Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson's patients, but other causes may exist. Most scientists involved with Parkinson's research do agree, however, that such promising early results provide a basis for further testing.
Which of the following statements regarding a high level of alpha-synuclein is supported by the passage?
A:It is not a cause for the death of neurons in Parkinson`s patients, though it has led to other research that may prove fruitful.
B:Its effect on human neurons cannot be tested.
C:It is one possible cause for the death of neurons in Parkinson`s patients, but not the only one.
D:Its detrimental effect on human neurons can be prevented through drug therapy.
E:It is the only possible cause for the death of neurons in Parkinson`s patients.
参考答案及共享解析
共享解析来源为网络权威资源、GMAT高分考生等； 如有疑问，欢迎在评论区提问与讨论
本题耗时：
已选答案：
正确答案：
C:It is one possible cause for the death of neurons in Parkinson`s patients, but not the only one.
定位：Alpha-synuclein toxicity seems to be one cause for the death of dopamine-producing neurons in Parkinson`s patients, but other causes may exist.
C正确
加入收藏
在线答疑
题目来源
Manhattan
